Physiological Role
Triglycerides are lipid molecules composed of a glycerol backbone linked to three fatty acids. They represent the body’s main energy reserve. After a meal, dietary fatty acids are assembled into triglycerides in enterocytes (cells lining the intestinal wall) and then transported in the blood by chylomicrons, large lipoproteins.
The liver also synthesises triglycerides by esterifying fatty acids with glycerol; some fatty acids can be produced from energy substrates through de novo lipogenesis. These hepatic triglycerides are exported into the circulation by VLDL (very low-density lipoproteins). In peripheral tissues, an enzyme called lipoprotein lipase hydrolyses triglycerides to release fatty acids that serve as an energy source.
In the Singular protocol, fasting triglyceride levels provide information about the balance between hepatic production and plasma clearance. They are particularly sensitive to the carbohydrate and lipid composition of the diet, as well as to insulin sensitivity.
Reference Ranges
Depending on the biomarker, Singular ranges are based on a synthesis of nutritional or clinical reference points and longevity research. They do not replace your laboratory's reference values or your healthcare professional's advice.
Biological Significance
In Singular, the zone labelled “optimal” corresponds to an internal calibration of the marker. A value in this zone is not sufficient, on its own, to conclude that fatty acids are properly mobilised, stored and used by the body. It is interpreted alongside the rest of the panel and the clinical context, without guaranteeing long-term cardiovascular health.
Elevated values signal an excess of triglyceride-rich particles in the circulation. This accumulation is associated with increased cardiovascular risk in observational studies. High triglycerides frequently accompany insulin resistance, excess body weight or a diet rich in refined sugars.
Values classified as “very high” by Singular warrant careful interpretation in the context of the panel. This internal label does not, on its own, indicate severe hypertriglyceridaemia or a genetic origin.
Longitudinal monitoring provides more insight than a single measurement. Tracking triglyceride levels across successive panels reveals the concrete impact of dietary adjustments and lifestyle changes.
Influencing Factors
Diet. Refined carbohydrates, added sugars and high fructose intakes may contribute to increased triglycerides, particularly in the context of excess energy intake. A diet rich in fibre, unsaturated fatty acids and lean protein may contribute to a more favourable lipid profile.
Alcohol. Alcohol consumption may raise triglycerides; the effect varies according to the amount consumed and the individual context. Its metabolism by the liver may promote fatty acid synthesis.
Physical activity. Regular exercise, particularly endurance activity, improves plasma triglyceride clearance by activating muscle lipoprotein lipase. The magnitude and duration of the response vary according to the session and the individual.
Body composition. Visceral adiposity is a major factor in chronic triglyceride elevation. A gradual reduction in abdominal fat tissue is frequently accompanied by an improved lipid profile.
Sleep. Insufficient or poor-quality sleep is associated with disturbances in metabolic regulation, including insulin and cortisol regulation, which may accompany variations in triglycerides.
Omega-3 (EPA+DHA). Long-chain omega-3 fatty acids, included in the Singular formula, contribute to the maintenance of normal blood triglyceride levels. This claim is authorised for a daily combined intake of 2 g of EPA and DHA.
In the Singular Formula
Triglycerides are among the lipid markers that the Singular formulation engine uses to adjust the nutritional response. Their role in personalisation is based on explicitly defined internal rules.
When triglyceride levels fall in the elevated zone, the formulation engine delivers dietary guidance content; on this criterion alone, taurine and omega-3 (EPA+DHA) remain at their base dosage. In the very elevated zone, a second rule raises both taurine and omega-3 to their reinforced dosage. Omega-3 fatty acids contribute to the maintenance of normal blood triglyceride levels, for a daily combined intake of 2 g of EPA and DHA.
Triglycerides are reported with other lipid profile markers measured by Singular. Apolipoprotein B provides information on the total number of atherogenic particles in circulation. HDL cholesterol completes the reading by assessing reverse cholesterol transport. Each of these three markers opens its own rule, independently of the other two. Separate crossings between triglycerides, HOMA-IR and liver enzymes may trigger lifestyle guidance without changing dosages.
The link between triglycerides and carbohydrate metabolism is also taken into account. Fasting glucose and fasting insulin are measured in the Singular panel; HOMA-IR is calculated from these two values to contribute to the assessment of insulin sensitivity, a parameter closely correlated with triglyceride levels.
Linked Bioactives
Scientific Studies
| Authors | Year | Type | Journal | |
|---|---|---|---|---|
| Nordestgaard BG et al. | 2007 | Cohort Study | JAMA | View on PubMed |
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women Copenhagen prospective study of 13,981 adults, with follow-up extending to approximately 26 years. Non-fasting triglycerides were associated with the risk of myocardial infarction, ischaemic heart disease and death, with differences between women and men. | ||||
| Sarwar N et al. | 2007 | Meta-analysis | Circulation | View on PubMed |
Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies Meta-analysis of 29 cohorts including 262,525 participants and 10,158 coronary events. The association between triglycerides and coronary risk was attenuated after adjustment for other risk factors, including HDL cholesterol. | ||||
| Marston NA et al. | 2019 | Meta-analysis | Circulation | View on PubMed |
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials Systematic review and meta-regression of 49 randomised trials. The association between triglyceride lowering and reduced cardiovascular risk was influenced by REDUCE-IT and became statistically borderline after its exclusion; this analysis defines neither a target range nor a nutritional action. | ||||
| Klempfner R et al. | 2016 | Cohort Study | Circulation: Cardiovascular Quality and Outcomes | View on PubMed |
Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry Observational 22-year follow-up of 15,355 people with established coronary heart disease. The 68% higher all-cause mortality concerned the ≥500 mg/dL group compared with the <100 mg/dL group. An erratum was published under PMID 27650352. | ||||
| Zhou H et al. | 2022 | Cohort Study | Journal of the American Heart Association | View on PubMed |
Associations of Hypertriglyceridemia Onset Age With Cardiovascular Disease and All-Cause Mortality in Adults: A Cohort Study In this Chinese Kailuan cohort, which was 82.2% male and defined hypertriglyceridaemia as ≥2.3 mmol/L, onset before age 45 was associated with higher cardiovascular disease and all-cause mortality risk; the mortality estimate had a wide confidence interval. | ||||
| Blais JE et al. | 2023 | Meta-analysis | Drugs | View on PubMed |
Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials Meta-analysis of 18 randomised placebo-controlled trials including 1,788 participants over 4 to 24 weeks, conducted mainly in China or Hong Kong. The mean triglyceride reduction was −0.34 mmol/L; these trials assessed neither clinical events nor long-term safety. | ||||
| Skulas-Ray AC et al. | 2019 | Review | Circulation | View on PubMed |
Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association American Heart Association science advisory on prescription omega-3 at 4 g per day and its effect on the triglyceride marker. It does not address the Singular formula or over-the-counter supplements, a clinical outcome, or the Singular tier threshold. | ||||